- Home
- CADL
as 07-26-2024 4:00pm EST
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | NEEDHAM |
| Market Cap: | 185.2M | IPO Year: | 2021 |
| Target Price: | $11.00 | AVG Volume (30 days): | 553.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.66 - $14.30 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Candel Therapeutics Inc. (CADL)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Barone Francesca | CADL | Chief Scientific Officer | Jul 17 '24 | Sell | $6.47 | 14,051 | $90,946.50 | 159,961 | SEC Form 4 |
| Nichols William Garrett | CADL | Chief Medical Officer | Jul 17 '24 | Sell | $6.47 | 10,875 | $70,389.53 | 114,482 | SEC Form 4 |
| Tyagarajan Seshu | CADL | Chief Technology Officer | Jul 17 '24 | Sell | $6.47 | 14,851 | $96,124.58 | 146,049 | SEC Form 4 |
| Schoch Charles | CADL | See Remarks | Jul 17 '24 | Sell | $6.47 | 9,884 | $63,975.18 | 62,520 | SEC Form 4 |
| Tak Paul Peter | CADL | Chief Executive Officer | Jul 11 '24 | Sell | $5.97 | 20,293 | $121,218.21 | 353,263 | SEC Form 4 |
Latest Candel Therapeutics Inc. News
CADL Breaking Stock News: Dive into CADL Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
ACCESSWIRE
a month ago
Candel Therapeutics' (NASDAQ:CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
GlobeNewswire
2 months ago
Candel Therapeutics to Join Russell 3000® Index
CNW Group
2 months ago
Lotto 6/49 - $64 million up for grabs in the next draw!
Simply Wall St.
2 months ago
Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
AFP
2 months ago
Seoul says it will resume loudspeaker propaganda against North
Simply Wall St.
2 months ago
It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
Simply Wall St.
2 months ago
OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
Compare CADL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CADL Candel Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.